

-continued

---

Cys	His	Gln	Leu	Cys	Ala	Arg	Gly	His	Cys	Trp	Gly	Pro	Gly	Pro
1				5					10					15
<hr/>														
Thr	Gln	Cys	Val	Asn	Cys	Ser	Gln	Phe	Leu	Arg	Gly	Gln	Glu	Cys
				20					25					30
<hr/>														
Val	Glu	Glu	Cys	Arg	Val	Leu	Gln	Gly	Leu	Pro	Arg	Glu	Tyr	Val
				35					40					45
<hr/>														
Asn	Ala	Arg	His	Cys	Leu	Pro	Cys	His	Pro	Glu	Cys	Gln	Pro	Gln
				50					55					60
<hr/>														
Asn	Gly	Ser	Val	Thr	Cys	Phe	Gly	Pro	Glu	Ala	Asp	Gln	Cys	Val
				65					70					75
<hr/>														
Ala	Cys	Ala	His	Tyr	Lys	Asp	Pro	Pro	Phe	Cys	Val	Ala	Arg	Cys
				80					85					90
<hr/>														
Pro	Ser	Gly	Val	Lys	Pro	Asp	Leu	Ser	Tyr	Met	Pro	Ile	Trp	Lys
				95					100					105
<hr/>														
Phe	Pro	Asp	Glu	Glu	Gly	Ala	Cys	Gln	Pro	Cys	Pro	Ile	Asn	Cys
				110					115					120
<hr/>														
Thr	His	Ser	Cys	Val	Asp	Leu	Asp	Asp	Lys	Gly	Cys	Pro	Ala	Glu
				125					130					135
<hr/>														
Gln	Arg	Ala	Ser	Pro	Leu	Thr								
				140										

---

What is claimed is:

1. A method for treating HER2 expressing cancer comprising administering one or more fixed dose(s) of HER2 antibody to a human patient in an amount effective to treat the cancer, wherein the fixed dose is selected from the group consisting of approximately 420 mg, approximately 525 mg, approximately 840 mg, and approximately 1050 mg of the HER2 antibody, wherein the HER2 antibody comprises the variable light and variable heavy amino acid sequences in SEQ ID Nos. 3 and 4, respectively.

2. The method of claim 1 wherein the HER2 antibody is pertuzumab.

3. The method of claim 1 wherein the fixed dose is 420 mg of the HER2 antibody.

4. The method of claim 1 wherein the fixed dose is 840 mg of the HER2 antibody.

5. The method of claim 1 wherein the fixed dose is 1050 mg of the HER2 antibody.

6. The method of claim 1 wherein the fixed dose is 525 mg of the HER2 antibody.

7. The method of claim 1 wherein a fixed dose of the HER2 antibody is administered to the patient approximately every week, approximately every 2 weeks, approximately every 3 weeks, or approximately every 4 weeks.

8. The method of claim 7 wherein a fixed dose of the HER2 antibody is administered to the patient approximately every 3 weeks.

9. The method of claim 1 comprising administering a loading dose of approximately 840 mg of the HER2 antibody followed by one or more maintenance doses of approximately 420 mg of the HER2 antibody.

10. The method of claim 9 wherein the maintenance doses are administered approximately every 3 weeks.

11. The method of claim 1 comprising administering a loading dose of approximately 1050 mg of the HER2 antibody followed by one or more maintenance doses of approximately 525 mg of the HER2 antibody.

12. The method of claim 11 wherein the maintenance doses are administered approximately every 3 weeks.

13. The method of claim 1 wherein the HER2 antibody is a naked antibody.

14. The method of claim 1 wherein the HER2 antibody is an intact antibody.

15. The method of claim 1 wherein the HER2 antibody is an antibody fragment comprising an antigen binding region.

16. The method of claim 1 wherein the HER2 antibody is a humanized or human IgG1 antibody.

17. The method of claim 1 wherein the cancer displays HER2 expression, amplification, or activation.

18. The method of claim 1 wherein the cancer is ovarian, peritoneal, or fallopian tube cancer.

19. The method of claim 1 wherein the cancer is metastatic breast cancer (MBC).

20. The method of claim 1 wherein the cancer is non-small cell lung cancer (NSCLC).

21. The method of claim 1 wherein the cancer is prostate cancer.

22. The method of claim 1 wherein the cancer is colorectal cancer.

23. The method of claim 1 comprising administering a second therapeutic agent to the patient.

24. The method of claim 23 wherein the second therapeutic agent is selected from the group consisting of chemotherapeutic agent, different HER2 antibody, antibody directed against a different tumor associated antigen, anti-hormonal compound, cardioprotectant, cytokine, EGFR-targeted drug, anti-angiogenic agent, tyrosine kinase inhibitor, COX inhibitor, non-steroidal anti-inflammatory drug, farnesyl transferase inhibitor, antibody that binds oncofetal protein CA 125, HER2 vaccine, another HER targeting therapy, Raf or ras inhibitor, doxorubicin HCL liposome injection, topotecan, taxane, dual tyrosine kinase inhibitor, TLK286, EMD-7200, a medicament that treats nausea, a medicament that